1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 18,000 | 18,800 | 10:12 | |
| 18,000 | 18,800 | 09:57 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.01. | Anbio Biotechnology - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| ANBIO BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | Anbio Biotechnology - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.08.25 | Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System | 160 | GlobeNewswire (Europe) | FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering... ► Artikel lesen | |
| 14.03.25 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 14.03.2025 | 970 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.03.2025
Aktien
1 KYG0367B1059 Anbio Biotechnology
2... ► Artikel lesen | |
| 20.02.25 | Anbio Biotechnology Announces Closing of Initial Public Offering | 377 | GlobeNewswire (Europe) | Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the "Company" or "Anbio"), a global diagnostic company dedicated to the advancement of medical technology and the... ► Artikel lesen | |
| 19.02.25 | Anbio Biotechnology Prices IPO Of 1.60 Mln Class A Ordinary Shares At $5.00/shr | 776 | AFX News | WASHINGTON (dpa-AFX) - Anbio Biotechnology said that it has priced its initial public offering of 1.60 million Class A ordinary shares at a public offering price of US$5.00 per Class A Ordinary... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORGANIGRAM GLOBAL | 1,300 | +2,36 % | Organigram Global Inc: Organigram increases Phylos loan by $3-million (U.S.) | ||
| ASSEMBLY BIOSCIENCES | 21,600 | -0,92 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 156,05 | +0,29 % | Axsome Therapeutics, Inc.: Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 | ||
| COMPASS PATHWAYS | 5,550 | -1,77 % | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | ||
| ALTIMMUNE | 4,706 | -0,65 % | Altimmune closes $75 million registered direct offering | ||
| ACHIEVE LIFE SCIENCES | 3,620 | +2,40 % | Achieve Life Sciences Announced Granting of New Hire Inducement Awards | ||
| SELLAS LIFE SCIENCES | 3,250 | +2,04 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,399 | -5,45 % | XORTX Therapeutics Inc.: XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update | CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| KALA BIO | 0,462 | +4,29 % | KALA BIO, Inc.: KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint | -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related... ► Artikel lesen | |
| SCYNEXIS | 0,633 | +3,94 % | SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 | The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,300 | -4,17 % | Galectin Therapeutics Inc.: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March ... | NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 10,800 | -0,92 % | Neuer Geheimtipp aus der Biotech-Szene - Wave Life Sciences hat sich zu Wochenbeginn mehr als verdoppelt! | Ist ein neuer Abnehm-Star geboren? Wave Life Sciences könnte mit einem bisher einzigartigen Wirkstoff den Adipositas-Markt aufmischen. Ein Ansatz, der Fett abbaut, Muskeln erhält und die Konkurrenz... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 4,260 | +2,90 % | Ironwood Pharmaceuticals, Inc.: Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance | Expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million -
Ended Q4 2025 with greater than... ► Artikel lesen | |
| XERIS BIOPHARMA | 6,050 | -2,65 % | Xeris Biopharma expects full-year 2025 revenue above estimates | ||
| NEUROGENE | 14,620 | -4,76 % | Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin |
ANBIO BIOTECHNOLOGY gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +12,30 % bei einem Aktienkurs von 21,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANBIO BIOTECHNOLOGY finden Sie auf Wallstreet Online.